23 Hrs
Source:
Chicago Tribune
Source: Chicago Tribune
23 HrsChicago Tribune
Source: Chicago Tribune
23 HrsReady to play
Ready to play
A personalized vaccine created by Moderna and Merck reduced melanoma recurrence in a large late-stage trial. The development raises hope for a treatment that could extend survival for patients with this aggressive cancer.
Notice: This Is an AI-Generated Summary
Comments (0)